Gut-Brain Axis Summit 2017 will be a dedicated event to help large pharma, biotech, and academic researchers unlock the potential of the gut-brain axis in demonstrating disease causation and translating these findings into safe and effective therapeutic candidates.
The vision is to bring together leading experts from industry and academia to uncover key areas in gut-brain axis research including:
Benefits of attending include:
- Understanding the role of gut microbiota in brain development and behavior
Investigating the signalling pathways and mechanisms that allow for gut-brain communication
- Critically reviewing pre-clinical and clinical evidence that show microbiota-related effects
Discussing the role of infant gut microbiota development and long term behavioral modulations
- Outlining translational implications for the gut-brain axis to help develop commercially viable therapeutics and/or nutritional interventions
Key Speakers Include:
- Emeran Mayer, Oppenheimer Center for Neurobiology of Stress, Division of Digestive Diseases, UCLA
- Sarkis Mazmanian, Co-Founder and Professor, Axial Biotherapeutics, Inc. and Caltech
- Nancy Thornberry, CEO, Kallyope
Helene Savignac, Preclinical Group Leader, 4D Pharma PLC
- Joseph Petrosino, Chief Scientific Officer and Director, Alkek Center for Metagenomics and Microbiome Research, Diversigen and Baylor College of Medicine
- Rochellys Diaz Heijtz, Associate Professor, Department of Neuroscience, Karolinska Institutet
- Caitlin Cowan, Post-Doctoral Researcher, APC Microbiome Institute
The vision is to bring together leading experts from industry and academia to uncover key areas in gut-brain axis research including:
Benefits of attending include:
- Understanding the role of gut microbiota in brain development and behavior
Investigating the signalling pathways and mechanisms that allow for gut-brain communication
- Critically reviewing pre-clinical and clinical evidence that show microbiota-related effects
Discussing the role of infant gut microbiota development and long term behavioral modulations
- Outlining translational implications for the gut-brain axis to help develop commercially viable therapeutics and/or nutritional interventions
Key Speakers Include:
- Emeran Mayer, Oppenheimer Center for Neurobiology of Stress, Division of Digestive Diseases, UCLA
- Sarkis Mazmanian, Co-Founder and Professor, Axial Biotherapeutics, Inc. and Caltech
- Nancy Thornberry, CEO, Kallyope
Helene Savignac, Preclinical Group Leader, 4D Pharma PLC
- Joseph Petrosino, Chief Scientific Officer and Director, Alkek Center for Metagenomics and Microbiome Research, Diversigen and Baylor College of Medicine
- Rochellys Diaz Heijtz, Associate Professor, Department of Neuroscience, Karolinska Institutet
- Caitlin Cowan, Post-Doctoral Researcher, APC Microbiome Institute
